Zacks Research Brokers Lower Earnings Estimates for CRSP

Key Points

• Analysts at Zacks Research have lowered their Q2 2026 earnings forecast for CRISPR Therapeutics to ($1.60) per share, slightly down from the prior estimate of ($1.59).
• In its latest quarterly report, CRISPR Therapeutics posted an earnings miss with a reported EPS of ($1.58), well below the consensus estimate of ($1.27).
• Despite the earnings forecast reduction, CRISPR Therapeutics has a diverse range of therapeutic programs under its proprietary CRISPR/Cas9 gene-editing technology aimed at treating serious diseases.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research reduced their Q2 2026 earnings per share estimates for shares of CRISPR Therapeutics in a report released on Tuesday, July 29th. Zacks Research analyst R. Department now anticipates that the company will earn ($1.60) per share for the quarter, down from their previous estimate of ($1.59). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q3 2026 earnings at ($1.35) EPS, Q4 2026 earnings at ($1.21) EPS, FY2026 earnings at ($5.71) EPS, Q1 2027 earnings at ($1.53) EPS, Q2 2027 earnings at ($1.52) EPS and FY2027 earnings at ($5.20) EPS.

Several other equities research analysts have also weighed in on the company. Barclays dropped their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, July 8th. Finally, Bank of America reduced their price objective on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $70.07.

CRISPR Therapeutics Stock Up 6.4%

NASDAQ CRSP traded up $3.62 during trading hours on Thursday, hitting $59.71. The company had a trading volume of 2,167,046 shares, compared to its average volume of 2,574,989. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $71.13. The business has a fifty day simple moving average of $49.63 and a 200-day simple moving average of $43.41. The firm has a market cap of $5.16 billion, a P/E ratio of -13.20 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The company's quarterly revenue was up 71.6% on a year-over-year basis. During the same period last year, the business earned ($1.43) EPS.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc grew its holdings in CRISPR Therapeutics by 24.6% in the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company's stock valued at $45,000 after buying an additional 181 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in CRISPR Therapeutics by 1.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 22,066 shares of the company's stock valued at $1,073,000 after buying an additional 243 shares during the last quarter. SFE Investment Counsel grew its holdings in CRISPR Therapeutics by 5.8% in the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock valued at $221,000 after buying an additional 355 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in CRISPR Therapeutics by 7.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock valued at $215,000 after buying an additional 372 shares during the last quarter. Finally, Axxcess Wealth Management LLC grew its holdings in CRISPR Therapeutics by 4.0% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock valued at $351,000 after buying an additional 393 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Transactions at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,932 shares of the stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider owned 6,068 shares of the company's stock, valued at approximately $218,083.92. This represents a 39.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Simeon George acquired 989,812 shares of the stock in a transaction dated Wednesday, July 16th. The shares were bought at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the acquisition, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. The trade was a 133.69% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.